SERPINE1 and Hutchinson-Gilford progeria syndrome: Thus, while we acknowledge the limitation of the findings of the present work which were based only on in vitro analysis of human primary fibroblasts derived from HGPS patients, our data suggest that SerpinE1 inhibition (e.g. by TM441) could be exploited as a potential therapeutic tool to treat HGPS.